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ABSTRACT
Objective: To standardize a high-performance liquid chromatography (HPLC) method for the deter-
mination of rifampicin (RMP) and its major metabolite desacetyl rifampicin (DRMP) in plasma and
urine.
Material and Methods: A simple, specific and sensitive HPLC method was developed for the deter-
mination of RMP and DRMP in plasma and urine. Separation in both was achieved by reverse-
phase chromatography on a C
18 
column with a mobile phase composition of 0.05 M phosphate
buffer: acetonitrile (55:45 v/v) at 254 nm.
Results: The retention times of DRMP, RMP and Rifapentine (RPN), the internal standard were 2.9,
4.8 and 10.5 min respectively. The assay was linear from 0.25 to 15.0 µg ml-1 for plasma and 2.5 to
80.0 µg ml-1 for urine. Both intra-day and inter-day accuracy and precision data showed good
reproducibility.
Conclusion: The HPLC method described is sensitive, selective and linear for the wide range of
concentrations for RMP and DRMP in plasma and urine. Thus, the method developed is well suited
for the pharmacokinetic studies.
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Introduction
Rifampicin (3-[4-methyl piperazinyl-iminomethyl] rifamy-
cin SV; rifampin), a semi-synthetic drug, is the key sterilizing
component of highly effective short course antituberculous
regimens and has a unique role in the killing of semi-dormant
tubercle bacilli.1 Very few HPLC methods have been developed
for the quantification of RMP and its metabolite, DRMP in the
plasma2-4 and urine.5-8 These HPLC methods involve tedious
procedures which are time-consuming. Also, the microbiologi-
cal assay does not permit separate determination of RMP and
DRMP in biological fluids.9 Therefore, our aim was to stand-
ardize a method for the determination of RMP and DRMP in
biological fluids by modifying certain experimental conditions
of the existing methods to enable good resolution between
RMP and DRMP peaks with shorter run time. After a number
of trials using different combinations, we arrived at the present
mobile phase and wavelength. This method is modified from
the thin-layer chromatography method10 which outperformed
all the HPLC procedures in its precision when our laboratory
participated in the international network initiated by WHO Glo-
bal TB program for evaluating the RMP bioavailability of Fixed
Dose Combinations (FDC).11
Material and Methods
Chemicals: Pure RMP standard was obtained from Sigma
Chemicals Company (St.Louis, Mo, USA). DRMP and RPN were
gifted by Dr. G. A. Ellard, (BMRC, London), Acetonitrile, chlo-
roform and methanol used were of HPLC grade obtained from
Merck (Mumbai, India). The chemicals, potassium dihydrogen
orthophosphate, disodium hydrogen phosphate, citric acid and
ascorbic acid were of analytical grade. Deionized water was
processed through a Milli-Q water purification system
(Millipore, USA).
Chromatographic system: The HPLC system (Shimadzu
Corporation, Kyoto, Japan) consisted of two pumps (LC-10ATvp),
diode array detector (SPD-M10Avp) at 254 nm and system con-
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troller (SCL-10Avp). A rheodyne manual injector (Rheodyne,
Cotati, CA, USA) attached with a 20 µl sample loop was used
for loading the sample. ClassVP-LC workstation was used for
data collection and acquisition. The analytical column was a
LUNA C
18
, 250 X 4.6 mm ID, 5 µ particle size (Phenomenex,
Torrance, CA, USA) protected by security guard column, 4-mm
L X 3.0-mm ID (Lichrospher 100 RP-18e, Merck, Germany). The
mobile phase was 0.05 M potassium dihydrogen phosphate
buffer (pH 2.6): acetonitrile (55:45 v/v) with a flow rate of 1.2
ml min-1 at ambient temperature. The chromatogram was run
for 12 min. Unknown concentrations were derived from the lin-
ear regression analysis of the peak height ratios (analyte/inter-
nal standard) Vs. concentration curve. Linearity was verified
using estimates of correlation coefficient (r).
Preparation of standard solution: A stock standard so-
lution of RMP and DRMP was prepared by dissolving 10 mg of
each in 10 ml methanol containing 0.5 mg/ml of ascorbic acid.
A stock solution of RPN was prepared by dissolving 12.5 mg in
10 ml acetonitrile. The combined working standards of RMP
and DRMP in concentrations ranging from 0.25-15 µg ml-1 were
prepared by appropriate dilution with pooled plasma. The urine
standards ranging from 2.5-80 µg ml-1 were prepared in pooled
urine. The internal standard was diluted in acetonitrile to give
a concentration of 1.25 mg/10 ml for usage in the plasma as-
say. The stock solution of 12.5 mg/10 ml as such was used in
the urine assay.
Sample preparation: An aliquot of 200 µl of blank plasma,
standard or test samples was pipetted into an eppendorf’s
tube of 1.5 ml capacity which contained 20 µl of 1.25 mg/10
ml of RPN. Acetonitrile (300 µl) was added, vortexed for one
minute and microcentrifuged at 10,000 rpm for 5 min. Then,
300 µl of the supernatant was taken into another
microcentrifuge tube and vacuum dried in the HETO vacuum
centrifuge (Allerod, Denmark). The residue obtained was re-
constituted in 100 µl of mobile phase and 20 µl volume was
injected.
An aliquot of 2.0 ml of blank urine, standard or test sam-
ple was added in a tube containing 40 µl of 12.5 mg/10 ml of
RPN. The contents were mixed with 1.0 ml of citrate-phos-
phate buffer (1.5 M, pH 7.0) and extracted with 2.0 ml chloro-
form by vortexing for one min. The volume of test sample taken
for assay varied for the samples containing concentrations
greater than 80 µg ml-1. The ratio of buffer to the volume of
sample was similar (1:2) and 2.0 ml of chloroform was used
uniformly for extraction. The mixture was centrifuged at 2500
rpm for 10 min. The aqueous layer was discarded and 500 µl
of chloroform extract was transferred to another glass tube
and evaporated at 600C in a water bath. The residue was re-
constituted in 500 µl of mobile phase and 20 ml volume was
injected.
Results
Under the chromatographic conditions described above,
the two compounds, DRMP and RMP were well separated from
each other as seen in the representative chromatogram (Fig-
ure 1). The mean retention time of DRMP, RMP and RPN was
2.9, 4.8 and 10.5 min respectively. Isoniazid, pyrazinamide
(PZA) and their metabolites and ethambutol (EMB), which are
often co-administered with RMP, did not interfere with the
chromatograms.
The calibration curves for DRMP and RMP in plasma were
plotted. These curves were found to be linear over the con-
centration range of 0.25 to 15 µg ml-1 with correlation coeffi-
cients (r) greater than 0.9996. In urine, the curve was linear
from 2.5 to 80 mg/l with r-value greater than 0.9943. The rela-
tive standard deviation (RSD) for calculated concentrations of
RMP assay in plasma and urine was less than 5% except for
2.5 µg ml-1 concentration in urine. However, the RSD for DRMP
was much greater ranging from 0.6 to 20.1% for plasma and
3.7 to 19.3% for urine, the greatest being for the lowest stand-
ard. The Limit of detection (LOD) and Limit of quantitation
(LOQ) estimated mathematically from the standard curve equa-
tion,12 were 0.1 and 0.25 µg ml-1 and 1.0 and 2.5 µg ml-1 for
the plasma and urine assays respectively.
The intra-day precision was measured by RSD of the daily
mean and it was less than 3.5 % at the three control concen-
trations in plasma RMP and two control preparations in DRMP.
The RSD of the lowest control of DRMP was 11.6%. The intra-
day precision of the three control concentrations in urine was
better than that of plasma for both RMP and DRMP, the RSD
being less than 1.8%. The inter-day variability was highest for
plasma DRMP (<11%), the next being plasma RMP (<6.4%)
and much lower for urine RMP and DRMP ranging from 1.0 to
4.6%. These results suggest that reproducibility is much bet-
ter for the urine assay. The overall accuracy ranged from 94 to
102 %.
The recovery of RMP and DRMP was assessed by spiking
known concentrations to human plasma samples containing
Figure 2:  Concentrations of rifampicin and desacetyl rifampicin in
the plasma of one healthy volunteer after oral administration of 600
mg of rifampicin during 24 hours
Figure 1: Chromatograms of a) Blank; b) DRMP (5 µg ml-1) and RMP
(5 µg ml- 1)  in plasma and c) DRMP (39.2 µg ml-1) and RMP (45 µg
ml-1) in urine. [rmp - rifampicin; drmp - desacetyl rifampicin; rpn-
rifapentine]
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previously determined concentrations of RMP and DRMP. This
experiment was done only for plasma. The recovery ranged
from 100 to 104% for RMP and 90 to 113% for DRMP.
The method described was applied for the determination
of RMP and DRMP in the plasma and urine of a healthy volun-
teer following oral administration of 600 mg of RMP. Figure 2
shows the pharmacokinetic profile of plasma RMP and DRMP.
Rifampicin was detectable up to 24 h after the dose. In urine,
both RMP and DRMP were detectable beyond 24 h (data not
presented).
Discussion
It is important to measure RMP as well as DRMP because
DRMP has an antimycobacterial activity closely similar to
RMP. Moreover, HPLC procedures that could efficiently sepa-
rate and accurately measure both compounds were thought
to be more robust and precise than those designed to meas-
ure only RMP. Lastly, it was hoped that calculated plasma
and urine DRMP/RMP ratios and exploring their changes with
time might uncover individual patterns in RMP desacetylation.
Hence, the experimental conditions were optimized to per-
mit good resolution between DRMP and RMP peaks with
shorter run time. The mobile phase varied by changing the
proportion of acetonitrile to the buffer. Increasing the pro-
portion of acetonitrile (65%) eluted DRMP close to the sol-
vent front while decreasing the proportion (35%) resulted in
the peaks being wide apart with double the retention time
and decrease in the height. The best resolution was obtained
using 45% of acetonitrile. Extraction of urinary RMP and
DRMP with chloroform instead of acetonitrile eliminated the
contaminants and thereby prevented contamination of the
column. The UV spectrum of RMP depends on the nature of
the mobile phase. The wavelength set at 254 nm was com-
pared with 215 and 340 nm. At 254 nm, less interfering peaks
were observed than at 215 nm and more peak height than at
340 nm.
There has been an increasing demand for a suitable method
for the assay of RMP and DRMP in biological fluids of patients
taking this drug. However, currently only the limited assay
procedure for RMP and DRMP quantitation by HPLC are avail-
able and these involve cumbersome and time-consuming ex-
traction procedures. Attempts were made to simplify and im-
prove the assay methods by the use of the simple extraction
procedure. Hence, the HPLC method described is sensitive,
selective and linear for the wide range of concentrations for
RMP and DRMP in plasma and urine. The detection limit of 1.0
µg ml-1 for urine assay enables the method to identify non-
compliance with RMP therapy in tuberculosis patients. This
precise and simple method utilizes a single step extraction.
The chromatogram has a good resolved peak for DRMP in urine
with good intra- and inter-day precision. The urinary-based
approach for assessing the relative bioavailability of rifampicin
in FDC antituberculosis formulations has been shown to be
satisfactory.13  The method described can be used to monitor
RMP concentrations in patients who are administered ri-
fampicin-containing regimens.
Acknowledgement
The authors acknowledge the support and valuable suggestions provided by Dr. V.
Kumaraswamy, in preparing the manuscript. We also thank Mr. B. Doraiswamy for
his secretarial assistance.
References
1. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimen-
tal short course chemotherapy. Bull Int Union Tuberc 1978;53:5-12.
2. Smith PJ, van Dyk J, Fredericks A. Determination of rifampicin, isoniazid and
pyrazinamide by high performance liquid chromatography after their simulta-
neous extraction from plasma. Int J Tuberc Lung Dis 1999;3:325-8.
3. Ishi M, Ogata H. Determination of rifampicin and its main metabolites in hu-
man plasma by high-performance liquid chromatography. J Chromatogr
1988;426:412-6.
4. Ratti B, Parenti RR, Toselli A, Zerilli LF. Quantitative assay of rifampicin and its
metabolite 25-desacetyl rifampicin in human plasma by reverse-phase high
performance liquid chromatography. J Chromatogr 1981;225: 526-31.
5. Lecaillon JB, Febvre N, Metayer JP, Souppart C. Quantitative assay of rifampicin
and three of its metabolites in human plasma, urine and saliva by high-per-
formance liquid chromatography. J Chromatogr 1978;145: 319-24.
6. Oldfield S, Berg JD, Stiles HJ, Buckley BM. Measurements of rifampicin and
25-desacetyl rifampicin in biological fluids using high-performance liquid chro-
matography with direct sample injection. J Chromatogr 1986; 377:423-9.
7. Panchagnula R, Sood A, Sharda N, Kaur K, Kaul CL. Determination of rifampicin
and its main metabolite in plasma and urine in presence of pyrazinamide and
isoniazid by HPLC method. J Pharm Biomed Anal 1999;18:1013-20.
8. Weber A, Opheim KE, Smith AL, Wong K. High pressure liquid chromatographic
quantitation of rifampicin and its two major metabolites in urine and serum.
Rev Infect Dis 1983;5:433-9.
9. Dicksons J M, Aber V R, Allen B W, Ellard G A, Michison D A. Assay of ri-
fampicin in serum. J Clin Pathol 1974;27:452-62.
10. Immanuel C, Jayasankar K, Narayana ASL, Sarma GR. Self-induction of ri-
fampicin metabolism in man. Indian J Med Res 1985;82:381-7.
11. Ellard GA. The evaluation of rifampicin bioavailabilities of fixed-dose combina-
tions of antituberculosis drugs: Procedures for ensuring laboratory proficiency.
Int J Tubercle Lung Dis 1999;3:322-4.
12. Chenevier P, Massias L, Gueylard D, Farinotti R. Determination of ethambutol
in plasma by high performance liquid chromatography after pre-column
derivatization. J Chromatogr B Biomed Sci Appl 1998;708:310-5.
13. Pillai G, Ellard GA, Smith PJ, Fourie PB. The potential use of urinary excretion
data for assessing the relative bioavailability of rifampicin in fixed dose combi-
nation antituberculosis formulations. Int J Tuberc Lung Dis 2001;5:691-5.
Quantitation of rifampicin and desacetyl rifampicin by HPLC
Indian J Pharmacol | August 2004 | Vol 36 | Issue 4 | 231-233
